PDCD1 and neoplasm: The rationale behind this observation may be related to the fact that in earlier stages of the disease, the tumor burden is relatively lower, and the immune system may be less compromised, thus allowing for a more robust antitumor immune response to be elicited by PD-1 inhibitors.